Phase III randomized, open-label study comparing the efficacy and safety of AG-221 vs conventional care regimens (CCR) in older patients with advanced acute myeloid leukemia (AML) with isocitrate dehydrogenase (IDH)-2 mutations in relapse or refractory to multiple prior treatments: The IDHENTIFY trial Meeting Abstract
| Authors: | Tallman, M. S.; Knight, R. D.; Glasmacher, A. G.; Dohner, H. |
| Abstract Title: | Phase III randomized, open-label study comparing the efficacy and safety of AG-221 vs conventional care regimens (CCR) in older patients with advanced acute myeloid leukemia (AML) with isocitrate dehydrogenase (IDH)-2 mutations in relapse or refractory to multiple prior treatments: The IDHENTIFY trial |
| Meeting Title: | 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 34 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2016 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2016-05-20 |
| Start Page: | 393s |
| Language: | English |
| ACCESSION: | WOS:000404711504209 |
| DOI: | 10.1200/JCO.2016.34.15_suppl.TPS7074 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: TPS7074 -- Source: Wos |
